Related Experiment Video
Updated: Jun 22, 2026
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
New results from the use of bisphosphonates in cancer patients
Robert Coleman1, Michael Gnant
1Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, WhithamRoad, Sheffield S103LZ, UK. r.e.coleman@sheffield.ac.uk
Purpose Of Review:
Metastatic bone disease results from cancer-bone cell interactions in the bone marrow microenvironment rather than direct destruction by cancer cells. Additionally, cancer treatments may have adverse effects on bone health. Therefore, a clear rationale exists for bone-targeted therapies to prevent skeletal complications and potentially modify the underlying disease.
Recent Findings:
Studies in metastatic disease have focused on refining treatment, largely through the use of bone metabolism markers. Use of bisphosphonates in early cancer has become increasingly important to prevent bone loss. Recent results, notably with zoledronic acid, indicate that bone mineral density can be maintained and increased bone turnover normalized. Bisphosphonates are potent inhibitors of bone osteolysis and may impede both the development of bone metastases and survival of dormant cells in the marrow microenvironment. Additionally, bisphosphonates may have direct effects on tumour cells, especially in combination with chemotherapy. Clinical trial results in breast cancer with clodronate were inconclusive, but recent data with zoledronic acid suggest that bisphosphonates may indeed modify the course of the disease.
Summary:
The roles of bisphosphonates in metastatic bone disease and the prevention of cancer treatment induced bone loss have been defined. However, results from ongoing metastasis prevention trials are required before routine adjuvant bisphosphonates can be recommended.
Insights
Bisphosphonates help prevent bone loss from cancer treatments and may slow bone metastasis. Further research is needed to confirm their role in preventing cancer spread and improving patient outcomes.
Area of Science:
- Oncology
- Bone Biology
- Pharmacology
Background:
- Metastatic bone disease arises from complex cancer-bone cell interactions within the bone marrow microenvironment.
- Cancer therapies can negatively impact bone health, necessitating bone-targeted interventions.
- Preventing skeletal complications and potentially modifying disease progression are key goals.
Purpose of the Study:
- To review the current understanding of bisphosphonates in managing metastatic bone disease.
- To evaluate the efficacy of bisphosphonates in preventing cancer treatment-induced bone loss.
- To assess the potential of bisphosphonates to modify the course of metastatic cancer.
Main Methods:
- Review of studies focusing on bone metabolism markers in metastatic disease.
- Analysis of clinical trial data on bisphosphonate use in early and advanced cancer.
- Examination of bisphosphonates' effects on bone osteolysis and tumor cell interactions.
Main Results:
- Bisphosphonates, particularly zoledronic acid, can maintain or increase bone mineral density and normalize bone turnover.
- These agents inhibit bone osteolysis, potentially hindering bone metastasis development and dormant cell survival.
- Emerging data suggest bisphosphonates may directly impact tumor cells, especially with combined chemotherapy.
Conclusions:
- The roles of bisphosphonates in metastatic bone disease and preventing treatment-related bone loss are established.
- Ongoing trials are crucial to determine if routine adjuvant bisphosphonate use can prevent metastasis.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:31Osteoclasts in Bone Remodeling